Profile data is unavailable for this security.
About the company
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
- Revenue in GBP (TTM)55.66m
- Net income in GBP-35.65m
- Incorporated2004
- Employees602.00
- LocationAllergy Therapeutics PLCDominion WayWORTHING BN14 8SAUnited KingdomGBR
- Phone+44 190 384 4700
- Fax+44 190 384 4726
- Websitehttps://www.allergytherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hVIVO PLC | 62.73m | 10.65m | 75.57m | 301.00 | 7.11 | 1.68 | 5.32 | 1.20 | 0.0155 | 0.0155 | 0.0911 | 0.0657 | 0.7289 | -- | 4.20 | 208,388.70 | 12.38 | 5.51 | 20.28 | 10.35 | -- | -- | 16.98 | 6.73 | 1.86 | -- | 0.2241 | 67.09 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Scancell Holdings Plc | 0.00 | -15.81m | 98.49m | 61.00 | -- | -- | -- | -- | -0.0171 | -0.0171 | 0.00 | -0.015 | 0.00 | -- | -- | 0.00 | -81.40 | -31.66 | -625.06 | -37.66 | -- | -- | -- | -822.37 | -- | -42.23 | 251.00 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Avacta Group Plc | 11.26m | -29.43m | 119.93m | 151.00 | -- | 12.34 | -- | 10.65 | -0.085 | -0.1496 | 0.0327 | 0.0251 | 0.1854 | 0.00 | 2.64 | 74,576.16 | -48.46 | -43.48 | -172.33 | -78.27 | 44.59 | 63.54 | -261.32 | -781.44 | 1.08 | -0.5712 | 0.7229 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Bioventix PLC | 13.66m | 7.85m | 143.68m | 17.00 | 18.57 | 12.73 | 18.06 | 10.52 | 1.48 | 1.48 | 2.58 | 2.16 | 1.04 | 2.17 | 2.21 | 803,738.30 | 59.98 | 58.33 | 69.06 | 63.62 | 90.95 | 93.09 | 57.42 | 64.12 | 6.69 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| 4Basebio PLC | 933.00k | -12.33m | 152.64m | -- | -- | 5.78 | -- | 163.60 | -0.9391 | -0.9391 | 0.0711 | 1.70 | 0.0329 | 0.8584 | 4.78 | -- | -43.54 | -36.81 | -48.26 | -40.98 | 67.52 | 69.88 | -1,321.87 | -1,160.83 | 11.18 | -19.68 | 0.3658 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -22.15m | 213.28m | 25.00 | -- | -- | -- | -- | -0.2647 | -0.2647 | 0.00 | -0.0797 | 0.00 | -- | -- | 0.00 | -227.96 | -227.46 | -- | -1,738.54 | -- | -- | -- | -- | -- | -2.58 | 5.15 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Puretech Health PLC | 3.52m | 39.02m | 303.89m | 56.00 | 7.29 | 1.00 | 13.29 | 86.32 | 0.1737 | 0.1737 | 0.0138 | 1.26 | 0.0075 | -- | 2.48 | 62,865.73 | 4.29 | -3.27 | 4.57 | -3.83 | -- | -- | 575.43 | -253.25 | -- | -- | 0.052 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Oxford BioMedica plc | 128.80m | -43.19m | 335.36m | 861.00 | -- | 5.87 | -- | 2.60 | -0.414 | -0.414 | 1.24 | 0.5384 | 0.5322 | 5.73 | 4.71 | 149,590.00 | -20.09 | -20.23 | -25.99 | -25.48 | 41.17 | 49.36 | -37.74 | -45.03 | 2.05 | -5.42 | 0.6426 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Allergy Therapeutics plc | 55.66m | -35.65m | 347.95m | 602.00 | -- | -- | -- | 6.25 | -0.0075 | -0.0075 | 0.0117 | -0.0015 | 0.7836 | 2.15 | 6.00 | 92,453.49 | -50.19 | -22.88 | -78.92 | -30.15 | 54.04 | 66.47 | -64.05 | -24.88 | 1.15 | -4.07 | 1.19 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Genus plc | 671.60m | -4.00m | 1.35bn | 3.44k | -- | 2.61 | 34.28 | 2.01 | -0.0612 | -0.0612 | 10.16 | 7.82 | 0.6585 | -- | 6.11 | 195,289.30 | -0.6275 | 3.30 | -0.7199 | 3.87 | -- | -- | -0.953 | 4.98 | 1.33 | -- | 0.3656 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Chase Bank, NA (Investment Management)as of 01 Mar 2025 | 129.00m | 2.71% |
| West Yorkshire Pension Fundas of 01 Mar 2025 | 13.88m | 0.29% |
| IG Markets Ltd.as of 01 Mar 2025 | 8.90m | 0.19% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 2025 | 8.42m | 0.18% |
| Santander Asset Management SA SGIICas of 01 Mar 2025 | 4.42m | 0.09% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Mar 2025 | 4.22m | 0.09% |
| Banque Pictet & Cie SAas of 01 Mar 2025 | 2.53m | 0.05% |
| Raiffeisen Kapitalanlage-Gesellschaft mbHas of 01 Mar 2025 | 2.42m | 0.05% |
| iDealing.com Ltd.as of 01 Mar 2025 | 1.45m | 0.03% |
| Bank Julius B�r & Co. AGas of 01 Mar 2025 | 1.39m | 0.03% |
